Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
US biopharma company Antios Therapeutics has initiated its first-in-human phase 1 clinical trial for ATI-2173, a liver-targeted, orally-administered, small molecule against hepatitis B. The phase 1a study is a randomized, double-blind, placebo-controlled single-ascending dose (SAD) study that will feature healthy volunteers to assess the safety, tolerability and pharmacokinetic profile of the compound. The SAD trial […]